Summary
This narrative review synthesises current knowledge on therapeutic options for Mycobacterium abscessus infections, a major clinical challenge in cystic fibrosis populations. The paper examines emerging treatments and novel drug delivery strategies in response to the organism's intrinsic resistance to multiple antibiotic classes and the limited efficacy of current regimens adapted from tuberculosis therapy. The authors argue that new approaches beyond traditional antimicrobial repurposing are urgently needed to improve clinical outcomes.
Regional applicability
Cystic fibrosis is recognised in UK clinical practice, and M. abscessus infection is an emerging concern in CF populations. Findings regarding therapeutic strategies would be directly relevant to UK respiratory medicine and CF centres, though implementation would depend on licensing and availability of novel therapeutics within the NHS.
Key measures
Therapeutic efficacy against M. abscessus; antibiotic resistance profiles; novel drug delivery mechanisms; innovative molecular approaches
Outcomes reported
The review analysed emerging and alternative treatments, novel drug delivery strategies, and innovative molecules for combating M. abscessus infections in cystic fibrosis patients. It addressed the challenge of antibiotic resistance and evaluated therapeutic approaches beyond repurposed tuberculosis medications.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.